Orbimed Capital GP VII LLC
SEC-identified person · CIK 1760648 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Imara Inc. IMRA | Director | filed 2020–2026 |
| Q32 Bio Inc. QTTB | Director | filed 2024–2026 |
| Keros Therapeutics, Inc. KROS | Director | filed 2020–2025 |
| Passage BIO, Inc. PASG | Officer | filed 2020–2025 |
| MBX Biosciences, Inc. MBX | Director | filed 2024–2025 |
| Venetian-1 Acquisition Corp. | Director | filed 2024–2024 |
| Terns Pharmaceuticals, Inc. TERN | Director | filed 2021–2024 |
| Kinnate Biopharma Inc. KNTE | Director | filed 2020–2024 |
| Theseus Pharmaceuticals, Inc. THRX | Director | filed 2021–2024 |
| Galecto, Inc. GLTO | Director | filed 2020–2023 |
| Third Harmonic Bio, Inc. THRD | Director | filed 2022–2022 |
| Sierra Oncology, Inc. SRRA | Director | filed 2019–2022 |
| Arcutis Biotherapeutics, Inc. ARQT | Director | filed 2020–2022 |
| Janux Therapeutics, Inc. JANX | Director | filed 2021–2021 |
| Repare Therapeutics Inc. RPTX | Director | filed 2020–2021 |
| Pandion Therapeutics, Inc. PAND | Officer | filed 2020–2020 |
| Fusion Pharmaceuticals Inc. FUSN | Director | filed 2020–2020 |
| Synthorx, Inc. THOR | Officer | filed 2018–2018 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.